Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Montelukast Sodium Market by Product Type (Montelukast Sodium Amorphous, Montelukast Sodium Crystalline) and by Dosage Form (Tablets, Chewable Tablets, Oral Solutions): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03142

Pages: NA

Charts: NA

Tables: NA

Montelukast sodium is a leukotriene inhibitory agent that is used for many indications that includes asthma, exercise induced bronchospasm, allergic rhinitis, primary dysmenorrhea and urticaria. It is generally used as a complementary therapy in adults along with inhaled corticosteroids, if the effect produced by corticoids are not optimum. Key factors driving the growth of this market are the rise in respiratory diseases coupled with the growing geriatric population. However, side effects related to montelukast sodium such as stomach pain, heartburn, upset stomach, nausea, and diarrhea will surely impede the market growth. Moreover, the increasing R&D investments to develop novel drugs and the advancements in technology will create lucrative opportunities for key market players.

The montelukast sodium market is segmented based on product type, dosage form and region. Based on product type this market is segmented into montelukast sodium amorphous and montelukast sodium crystalline. Further, based on dosage form this market is segmented into tablets, chewable tablets and oral solutions. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players of the market included in the report are Merck Sharp & Dohme Corp., Morepen Laboratories, Teva Pharmaceutical Industries Ltd., Mylan N.V., Roxane Laboratories, Inc., Glenmark Generics Ltd, Sandoz International GmbH, Vintage Pharmaceuticals Inc., Kudco Ireland Ltd., and Apotex Corp.

Key Benefits

  • The study provides an in-depth analysis of the global montelukast sodium market, with current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by product type elucidates the various forms of available montelukast sodium types.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.
  • By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

 Key Market Segments

  • By Product Type
    • Montelukast Sodium Amorphous
    • Montelukast Sodium Crystalline
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA
  • By Dosage Form
    • Tablets
    • Chewable Tablets
    • Oral Solutions

 
Key Market Players

  • Glenmark Generics Ltd.
  • Vintage Pharmaceuticals Inc.
  • Apotex Corp
  • Teva Pharmaceutical Industries Ltd.
  • Morepen Laboratories
  • Roxane Laboratories, Inc.
  • Mylan N.V.
  • Merck Sharp & Dohme Corp.
  • Sandoz International GmbH
  • Kudco Ireland Ltd.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: MONTELUKAST SODIUM MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Montelukast Sodium Amorphous

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Montelukast Sodium Crystalline

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: MONTELUKAST SODIUM MARKET, BY DOSAGE FORM

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Dosage Form

    • 5.2. Tablets

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Chewable Tablets

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Oral Solutions

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: MONTELUKAST SODIUM MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product Type

      • 6.2.3. Market Size and Forecast, By Dosage Form

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Montelukast Sodium Market

        • 6.2.5.1. Market Size and Forecast, By Product Type
        • 6.2.5.2. Market Size and Forecast, By Dosage Form

      • 6.2.6. Canada Montelukast Sodium Market

        • 6.2.6.1. Market Size and Forecast, By Product Type
        • 6.2.6.2. Market Size and Forecast, By Dosage Form

      • 6.2.7. Mexico Montelukast Sodium Market

        • 6.2.7.1. Market Size and Forecast, By Product Type
        • 6.2.7.2. Market Size and Forecast, By Dosage Form

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product Type

      • 6.3.3. Market Size and Forecast, By Dosage Form

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Montelukast Sodium Market

        • 6.3.5.1. Market Size and Forecast, By Product Type
        • 6.3.5.2. Market Size and Forecast, By Dosage Form

      • 6.3.6. Germany Montelukast Sodium Market

        • 6.3.6.1. Market Size and Forecast, By Product Type
        • 6.3.6.2. Market Size and Forecast, By Dosage Form

      • 6.3.7. Italy Montelukast Sodium Market

        • 6.3.7.1. Market Size and Forecast, By Product Type
        • 6.3.7.2. Market Size and Forecast, By Dosage Form

      • 6.3.8. Spain Montelukast Sodium Market

        • 6.3.8.1. Market Size and Forecast, By Product Type
        • 6.3.8.2. Market Size and Forecast, By Dosage Form

      • 6.3.9. UK Montelukast Sodium Market

        • 6.3.9.1. Market Size and Forecast, By Product Type
        • 6.3.9.2. Market Size and Forecast, By Dosage Form

      • 6.3.10. Russia Montelukast Sodium Market

        • 6.3.10.1. Market Size and Forecast, By Product Type
        • 6.3.10.2. Market Size and Forecast, By Dosage Form

      • 6.3.11. Rest Of Europe Montelukast Sodium Market

        • 6.3.11.1. Market Size and Forecast, By Product Type
        • 6.3.11.2. Market Size and Forecast, By Dosage Form

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product Type

      • 6.4.3. Market Size and Forecast, By Dosage Form

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Montelukast Sodium Market

        • 6.4.5.1. Market Size and Forecast, By Product Type
        • 6.4.5.2. Market Size and Forecast, By Dosage Form

      • 6.4.6. Japan Montelukast Sodium Market

        • 6.4.6.1. Market Size and Forecast, By Product Type
        • 6.4.6.2. Market Size and Forecast, By Dosage Form

      • 6.4.7. India Montelukast Sodium Market

        • 6.4.7.1. Market Size and Forecast, By Product Type
        • 6.4.7.2. Market Size and Forecast, By Dosage Form

      • 6.4.8. South Korea Montelukast Sodium Market

        • 6.4.8.1. Market Size and Forecast, By Product Type
        • 6.4.8.2. Market Size and Forecast, By Dosage Form

      • 6.4.9. Australia Montelukast Sodium Market

        • 6.4.9.1. Market Size and Forecast, By Product Type
        • 6.4.9.2. Market Size and Forecast, By Dosage Form

      • 6.4.10. Thailand Montelukast Sodium Market

        • 6.4.10.1. Market Size and Forecast, By Product Type
        • 6.4.10.2. Market Size and Forecast, By Dosage Form

      • 6.4.11. Malaysia Montelukast Sodium Market

        • 6.4.11.1. Market Size and Forecast, By Product Type
        • 6.4.11.2. Market Size and Forecast, By Dosage Form

      • 6.4.12. Indonesia Montelukast Sodium Market

        • 6.4.12.1. Market Size and Forecast, By Product Type
        • 6.4.12.2. Market Size and Forecast, By Dosage Form

      • 6.4.13. Rest of Asia Pacific Montelukast Sodium Market

        • 6.4.13.1. Market Size and Forecast, By Product Type
        • 6.4.13.2. Market Size and Forecast, By Dosage Form

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product Type

      • 6.5.3. Market Size and Forecast, By Dosage Form

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Montelukast Sodium Market

        • 6.5.5.1. Market Size and Forecast, By Product Type
        • 6.5.5.2. Market Size and Forecast, By Dosage Form

      • 6.5.6. South Africa Montelukast Sodium Market

        • 6.5.6.1. Market Size and Forecast, By Product Type
        • 6.5.6.2. Market Size and Forecast, By Dosage Form

      • 6.5.7. Saudi Arabia Montelukast Sodium Market

        • 6.5.7.1. Market Size and Forecast, By Product Type
        • 6.5.7.2. Market Size and Forecast, By Dosage Form

      • 6.5.8. UAE Montelukast Sodium Market

        • 6.5.8.1. Market Size and Forecast, By Product Type
        • 6.5.8.2. Market Size and Forecast, By Dosage Form

      • 6.5.9. Argentina Montelukast Sodium Market

        • 6.5.9.1. Market Size and Forecast, By Product Type
        • 6.5.9.2. Market Size and Forecast, By Dosage Form

      • 6.5.10. Rest of LAMEA Montelukast Sodium Market

        • 6.5.10.1. Market Size and Forecast, By Product Type
        • 6.5.10.2. Market Size and Forecast, By Dosage Form

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Merck Sharp And Dohme Corp.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Morepen Laboratories

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Teva Pharmaceutical Industries Ltd.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Mylan N.V.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Roxane Laboratories, Inc.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Glenmark Generics Ltd.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Sandoz International GmbH

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Vintage Pharmaceuticals Inc.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Kudco Ireland Ltd.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Apotex Corp

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL MONTELUKAST SODIUM MARKET, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL MONTELUKAST SODIUM MARKET FOR MONTELUKAST SODIUM AMORPHOUS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL MONTELUKAST SODIUM MARKET FOR MONTELUKAST SODIUM CRYSTALLINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL MONTELUKAST SODIUM MARKET, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL MONTELUKAST SODIUM MARKET FOR TABLETS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL MONTELUKAST SODIUM MARKET FOR CHEWABLE TABLETS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL MONTELUKAST SODIUM MARKET FOR ORAL SOLUTIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL MONTELUKAST SODIUM MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. NORTH AMERICA MONTELUKAST SODIUM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 12. U.S. MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 13. U.S. MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 14. CANADA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 15. CANADA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 16. MEXICO MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 17. MEXICO MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 18. EUROPE MONTELUKAST SODIUM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 21. FRANCE MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 22. FRANCE MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 23. GERMANY MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 24. GERMANY MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 25. ITALY MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 26. ITALY MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 27. SPAIN MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 28. SPAIN MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 29. UK MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 30. UK MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 31. RUSSIA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 32. RUSSIA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 33. REST OF EUROPE MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 34. REST OF EUROPE MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 35. ASIA-PACIFIC MONTELUKAST SODIUM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 38. CHINA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 39. CHINA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 40. JAPAN MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 41. JAPAN MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 42. INDIA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 43. INDIA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 44. SOUTH KOREA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 45. SOUTH KOREA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 46. AUSTRALIA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 47. AUSTRALIA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 48. THAILAND MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 49. THAILAND MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 50. MALAYSIA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 51. MALAYSIA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 52. INDONESIA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 53. INDONESIA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 56. LAMEA MONTELUKAST SODIUM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 59. BRAZIL MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 60. BRAZIL MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 61. SOUTH AFRICA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 62. SOUTH AFRICA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 63. SAUDI ARABIA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 64. SAUDI ARABIA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 65. UAE MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 66. UAE MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 67. ARGENTINA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 68. ARGENTINA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 69. REST OF LAMEA MONTELUKAST SODIUM, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 70. REST OF LAMEA MONTELUKAST SODIUM, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 71. MERCK SHARP AND DOHME CORP.: KEY EXECUTIVES
  • TABLE 72. MERCK SHARP AND DOHME CORP.: COMPANY SNAPSHOT
  • TABLE 73. MERCK SHARP AND DOHME CORP.: OPERATING SEGMENTS
  • TABLE 74. MERCK SHARP AND DOHME CORP.: PRODUCT PORTFOLIO
  • TABLE 75. MERCK SHARP AND DOHME CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 76. MOREPEN LABORATORIES: KEY EXECUTIVES
  • TABLE 77. MOREPEN LABORATORIES: COMPANY SNAPSHOT
  • TABLE 78. MOREPEN LABORATORIES: OPERATING SEGMENTS
  • TABLE 79. MOREPEN LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 80. MOREPEN LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 82. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 83. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 84. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 85. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. MYLAN N.V.: KEY EXECUTIVES
  • TABLE 87. MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 88. MYLAN N.V.: OPERATING SEGMENTS
  • TABLE 89. MYLAN N.V.: PRODUCT PORTFOLIO
  • TABLE 90. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. ROXANE LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 92. ROXANE LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 93. ROXANE LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 94. ROXANE LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 95. ROXANE LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. GLENMARK GENERICS LTD.: KEY EXECUTIVES
  • TABLE 97. GLENMARK GENERICS LTD.: COMPANY SNAPSHOT
  • TABLE 98. GLENMARK GENERICS LTD.: OPERATING SEGMENTS
  • TABLE 99. GLENMARK GENERICS LTD.: PRODUCT PORTFOLIO
  • TABLE 100. GLENMARK GENERICS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. SANDOZ INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 102. SANDOZ INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 103. SANDOZ INTERNATIONAL GMBH: OPERATING SEGMENTS
  • TABLE 104. SANDOZ INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 105. SANDOZ INTERNATIONAL GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. VINTAGE PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 107. VINTAGE PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 108. VINTAGE PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 109. VINTAGE PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 110. VINTAGE PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. KUDCO IRELAND LTD.: KEY EXECUTIVES
  • TABLE 112. KUDCO IRELAND LTD.: COMPANY SNAPSHOT
  • TABLE 113. KUDCO IRELAND LTD.: OPERATING SEGMENTS
  • TABLE 114. KUDCO IRELAND LTD.: PRODUCT PORTFOLIO
  • TABLE 115. KUDCO IRELAND LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. APOTEX CORP: KEY EXECUTIVES
  • TABLE 117. APOTEX CORP: COMPANY SNAPSHOT
  • TABLE 118. APOTEX CORP: OPERATING SEGMENTS
  • TABLE 119. APOTEX CORP: PRODUCT PORTFOLIO
  • TABLE 120. APOTEX CORP: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL MONTELUKAST SODIUM MARKET SEGMENTATION
  • FIGURE 2. GLOBAL MONTELUKAST SODIUM MARKET
  • FIGURE 3. SEGMENTATION MONTELUKAST SODIUM MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN MONTELUKAST SODIUM MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALMONTELUKAST SODIUM MARKET
  • FIGURE 11. MONTELUKAST SODIUM MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. MONTELUKAST SODIUM MARKET FOR MONTELUKAST SODIUM AMORPHOUS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. MONTELUKAST SODIUM MARKET FOR MONTELUKAST SODIUM CRYSTALLINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. MONTELUKAST SODIUM MARKET SEGMENTATION, BY BY DOSAGE FORM
  • FIGURE 15. MONTELUKAST SODIUM MARKET FOR TABLETS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. MONTELUKAST SODIUM MARKET FOR CHEWABLE TABLETS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. MONTELUKAST SODIUM MARKET FOR ORAL SOLUTIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 19. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 20. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 21. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 22. COMPETITIVE DASHBOARD
  • FIGURE 23. COMPETITIVE HEATMAP: MONTELUKAST SODIUM MARKET
  • FIGURE 24. TOP PLAYER POSITIONING, 2024
  • FIGURE 25. MERCK SHARP AND DOHME CORP.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 26. MERCK SHARP AND DOHME CORP.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 27. MERCK SHARP AND DOHME CORP.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 28. MOREPEN LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. MOREPEN LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. MOREPEN LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. MYLAN N.V.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. MYLAN N.V.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. ROXANE LABORATORIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. ROXANE LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. ROXANE LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. GLENMARK GENERICS LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. GLENMARK GENERICS LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. GLENMARK GENERICS LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. SANDOZ INTERNATIONAL GMBH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. SANDOZ INTERNATIONAL GMBH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. SANDOZ INTERNATIONAL GMBH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. VINTAGE PHARMACEUTICALS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. VINTAGE PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. VINTAGE PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. KUDCO IRELAND LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. KUDCO IRELAND LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. KUDCO IRELAND LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. APOTEX CORP: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. APOTEX CORP: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. APOTEX CORP: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Montelukast Sodium Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved